Joseph M Massaro Selected Research

high fluorescent intermediate II

1/2022	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
1/2022	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
1/2020	Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph M Massaro Research Topics

Disease

43	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 03/2003
31	Myocardial Infarction 01/2019 - 10/2004
24	Thrombosis (Thrombus) 10/2018 - 03/2007
23	Hypertension (High Blood Pressure) 01/2019 - 03/2003
19	Stroke (Strokes) 01/2021 - 08/2003
19	Hemorrhage 12/2019 - 10/2004
15	Heart Failure 01/2022 - 03/2013
11	Diabetes Mellitus 10/2018 - 07/2007
10	Inflammation (Inflammations) 01/2021 - 07/2004
10	Atherosclerosis 01/2017 - 08/2004
9	Coronary Disease (Coronary Heart Disease) 10/2017 - 11/2008
9	Obesity 12/2016 - 03/2003
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2013 - 07/2007
7	Coronary Artery Disease (Coronary Atherosclerosis) 01/2019 - 05/2010
7	Insulin Resistance 07/2013 - 01/2010
5	Chronic Renal Insufficiency 01/2019 - 03/2012
5	Acute Coronary Syndrome 10/2018 - 03/2012
5	Atrial Fibrillation 01/2018 - 10/2004
5	Ischemia 01/2018 - 03/2012
4	Ischemic Stroke 01/2020 - 08/2003
4	Dyslipidemias (Dyslipidemia) 01/2019 - 05/2011
4	Peripheral Arterial Disease 01/2017 - 01/2012
4	Non-alcoholic Fatty Liver Disease 01/2016 - 12/2008
3	Renal Artery Obstruction (Renal Artery Stenosis) 01/2019 - 01/2014
3	Type 2 Diabetes Mellitus (MODY) 08/2018 - 12/2008
3	Infarction (Infarctions) 05/2016 - 05/2014
3	Ventricular Remodeling 09/2012 - 05/2010
3	Death (Near-Death Experience) 05/2011 - 12/2010
2	Unstable Angina 08/2018 - 03/2012
2	Neoplasms (Cancer) 09/2017 - 01/2016
2	Cardiac Arrhythmias (Arrythmia) 01/2017 - 03/2012
2	Transient Ischemic Attack 01/2017 - 03/2004
2	Fatty Liver 01/2017 - 06/2010
2	Hypertriglyceridemia 01/2017 - 12/2014
2	Myocardial Ischemia (Ischemic Heart Diseases) 04/2016 - 05/2011
2	Hypercholesterolemia 02/2016 - 06/2009
2	Fibrosis (Cirrhosis) 01/2016 - 03/2011
2	Isolated Systolic Hypertension 01/2016 - 01/2014
1	Critical Illness (Critically Ill) 01/2021

Drug/Important Bio-Agent (IBA)

20	HDL CholesterolIBA 10/2018 - 03/2003
19	Triglycerides (Triacylglycerol)IBA 12/2016 - 07/2007
17	CalciumIBA 01/2021 - 11/2008
17	thienopyridineIBA 12/2019 - 12/2010
16	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 07/2007
13	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2005
13	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019 - 10/2004
11	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 10/2017 - 12/2010
9	LipidsIBA 10/2019 - 02/2008
8	C-Reactive ProteinIBA 10/2018 - 03/2004
8	CholesterolIBA 01/2018 - 02/2009
5	salicylhydroxamic acid (SHAM)IBA 01/2022 - 01/2018
5	CreatinineIBA 01/2019 - 03/2003
5	Cystatin CIBA 01/2019 - 03/2014
5	Streptokinase FDA Link 01/2017 - 05/2015
5	HDL LipoproteinsIBA 01/2016 - 02/2008
5	Insulin (Novolin)FDA Link 05/2014 - 12/2008
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2019 - 07/2015
4	Lipoproteins (Lipoprotein)IBA 01/2017 - 01/2016
4	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2017 - 05/2015
4	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 02/2016 - 12/2004
4	Antihypertensive Agents (Antihypertensives)IBA 01/2016 - 06/2009
3	high fluorescent intermediate IIIBA 01/2022 - 01/2020
3	DiureticsIBA 01/2020 - 09/2012
3	LDL CholesterolIBA 10/2019 - 06/2009
3	Sirolimus (Rapamycin)FDA Link 10/2018 - 03/2007
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 05/2013
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2018 - 01/2017
3	Paclitaxel (Taxol)FDA LinkGeneric 05/2017 - 03/2007
3	Warfarin (Coumadin)FDA LinkGeneric 10/2016 - 08/2003
3	Interleukin-6 (Interleukin 6)IBA 02/2016 - 12/2004
3	Transaminases (Aminotransferases)IBA 01/2016 - 12/2008
3	Alanine Transaminase (SGPT)IBA 01/2016 - 12/2008
3	MetalsIBA 10/2015 - 03/2007
3	PotassiumIBA 05/2014 - 03/2012
3	AdiponectinIBA 09/2012 - 05/2009
2	Plant NectarIBA 01/2022 - 01/2020
2	Indicators and Reagents (Reagents)IBA 10/2018 - 02/2008
2	PolymersIBA 10/2018 - 10/2017
2	Everolimus FDA Link 10/2018 - 10/2017
2	Biological ProductsIBA 01/2018 - 04/2009
2	Clopidogrel (Plavix)FDA Link 10/2016 - 12/2010
2	oxidized low density lipoproteinIBA 03/2016 - 12/2014
2	lipoprotein cholesterolIBA 03/2016 - 01/2016
2	AdipokinesIBA 02/2016 - 09/2012
2	IsoprostanesIBA 02/2016 - 02/2008
2	OsteoprotegerinIBA 02/2016 - 09/2010
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2016 - 08/2010
2	ResistinIBA 09/2012 - 05/2009
2	Fibrinogen (Factor I)FDA Link 10/2011 - 05/2010
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 10/2005 - 07/2004

Therapy/Procedure

26	Therapeutics 01/2022 - 02/2009
26	Stents 10/2018 - 03/2007
7	Catheters 01/2019 - 09/2010
6	Percutaneous Coronary Intervention 10/2018 - 12/2010
6	Drug-Eluting Stents 01/2016 - 03/2007
3	Duration of Therapy 05/2016 - 03/2015
3	Hormone Replacement Therapy (Therapy, Hormone Replacement) 11/2010 - 02/2008
2	Vagus Nerve Stimulation 01/2022 - 01/2020
2	Embolic Protection Devices 12/2012 - 04/2008
1	Art Therapy 01/2022